DFDA

Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy)

Treatment for Uterine Cancer

Typical Dosage: MPA 400-600mg daily, Megestrol Acetate 160mg 2-4 times daily

Effectiveness
35%
Safety Score
60%
Clinical Trials
40
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
MPA 400-600mg daily, Megestrol Acetate 160mg 2-4 times daily
Time to Effect
1-3 months
Treatment Duration
6-12 months or longer for recurrent disease
Evidence Quality
MODERATE
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$2,000
Side Effect Mgmt:$200
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$12,500/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$6,250
Cost per Remission
$10,000
Medroxyprogesterone Acetate (MPA) / Megestrol Acetate (Hormonal Therapy) Outcomes

for Uterine Cancer

Efficacy Outcomes
Overall Effectiveness
+35%
Response Rate
+40%
Remission Rate
+25%
Common Side Effects
Weight gain
+40%
Fluid retention
+30%
Hot flashes
+25%
Mood changes
+15%
Increased risk of venous thromboembolism
+7%

Sources:

nih.gov
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov